Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STALORAL Birch 300 IR in pediatric birch pollen‑induced allergic rhinoconjunctivitis
2023-509833-38-00Phase 3Completed
- Sponsor
- Stallergenes Greer
- Start
- May 2024
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) comparing STALORAL Birch 300 IR with Placebo (2 arms). Primary endpoint: Average ARC Total Combined Score (TCS0-38) over entire second birch pollen season (BPS2). Started May 2024; status: completed.
02
Drugs
allergenic extract of birch
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2023-509833-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509833-38-00.